AMPH

Amphastar Pharmaceuticals, Inc.

Fundamental data last updated:September 7, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

 


VALUATION

P/E

11.04

Market Cap ($M USD)

$850.99M

Forward P/E

7.85

PEG

0.19

PRICE TO SALES

1.18

PRICE TO BOOK

1.13

EV / EBITDA

8.76

5-Year Average P/E

Free Cash Flow Yield

15.89%

DCF Value

$85.28

Graham Number

$25.91

Price to FCF

6.29

EV to FCF

10.11

Earnings Yield

9.06%

FCF Yield

15.89%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$1.75

Next Year EPS Growth Estimate

$2.46

Next Year Revenue Growth Estimate

$844.00M

Return on Equity (ROE)

10.23%

FREE CASH FLOW

Operating Margin

16.20%

Debt-to-Equity

0.83

Piotroski F-Score

6

Altman Z-Score

2.19

Return on Invested Capital (ROIC)

7.87%

Current Ratio

3.85

Quick Ratio

2.82

Net Debt to EBITDA

3.30

Interest Coverage

4.53

Gross Profit margin

47.34%

FCF PER SHARE

$2.98

REVENUE PER SHARE

$15.90

Gainseekers Quantitative Analysis

Summary

Amphastar Pharmaceuticals appears dramatically undervalued when juxtaposed against its DCF Value of $90.97 and Graham Number of $25.91. The market’s current pricing suggests a significant mispricing, especially with a Forward P/E of 6.33 and an Earnings Yield of 9.20%, indicating robust earnings potential. The Altman Z-score of 2.18 suggests moderate financial health, but not without risk. This stock is a classic deep value play, with the market seemingly ignoring its intrinsic worth.

AI Exposure / Tech Reliance

In the rapidly evolving healthcare sector, Amphastar is well-positioned to leverage AI for drug development and manufacturing efficiencies. As a specialty and generic drug manufacturer, integrating AI could streamline operations and enhance precision. However, the industry’s regulatory landscape may slow tech adoption.

The Bull Case

For the value-driven investor, Amphastar offers compelling reasons to buy. With a ROIC of 7.87% and a Piotroski F-Score of 7, the company demonstrates strong capital efficiency and financial health. Its FCF Yield of 16.14% and robust operating margin of 16.20% highlight its ability to generate cash and maintain pricing power. These metrics suggest a well-managed company capable of delivering shareholder value.

The Bear Case

Despite its strengths, Amphastar faces notable risks. The stock's Price/Sales ratio of 1.16 and Price/Book of 1.11 may seem reasonable, but the technical indicators show it's trading significantly below its 52-week high, suggesting potential market skepticism. The zero dividend yield and payout ratio may deter income-focused investors, and the recent earnings surprise of -0.4% raises questions about earnings consistency. These factors could weigh heavily on investor sentiment.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Hold

Average Analyst Price Target

$23.00

Institutional Ownership %

1-Year Beta

0.97

Insider Buying % (6 Mo)

Distance to 52-Week High

61.97%

Distance to 52-Week Low

13.73%

EARNINGS SURPRISE %

-40.00%

50-DAY SMA

$20.22

200-DAY SMA

$24.84

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.